Many efforts have been made in the past to understand the function of lactose fines which are given as a ternary component to carrier-based dry powder inhaler formulations. It is undisputed that fines can significantly improve the performance of such formulations, but choosing the right amount of fines is a crucial point, because too high concentrations can have negative effects on the dispersion performance
Meggle has launched the new high-functionality excipient (HFE) CombiLac, a lactose-based, co-processed excipient, specifically designed to ease oral solid dosage form development and manufacture in direct compression (DC). See more at: http://www.contractpharma.com/contents/view_breaking-news/2015-05-13/meggle-introduces-triple-compound-combilac/#sthash.eH27ZowB.dpuf
Meggle Pharma: Soon we will introduce a world first: CombiLac® a triple compound which will ease formulations by combining diverging features. http://www.meggle-pharma.com/en/lactose/25-combilacsup-sup.html Does anybody know when it will be launched and more information is available?